Type 1 Diabetes Technology

Type 1 Diabetes (T1D) is a chronic autoimmune disease in which the immune system selectively destroys the insulin-producing beta cells located in the Islets of Langerhans within the pancreas. The result is absolute insulin deficiency, requiring lifelong exogenous insulin for survival. It accounts for approximately 5–10% of all diabetes cases globally, affecting an estimated 9 million people worldwide.

​

Classic Presenting Symptoms (the '4 Ts')

• Toilet — Polyuria: excessive, frequent urination including nocturia

• Thirsty — Polydipsia: extreme, unrelenting thirst from osmotic diuresis

• Tired — Profound fatigue due to cellular glucose starvation

• Thinner — Unexplained rapid weight loss as body catabolises fat and muscle

 

Additional Symptoms

• Blurred vision (osmotic lens changes)

• Genital thrush / skin infections (glucose-rich urine feeds yeasts)

• Slow wound healing

• Mood changes, irritability, difficulty concentrating

• ​

• Insulin Delivery Devices

• Insulin pens (reusable or disposable): standard delivery; half-unit dosing pens available for children and insulin-sensitive adults

• Smart insulin pens: Bluetooth-enabled pens (NovoPen 6, InPen) that log dose timing and amount; sync with CGM data

• Insulin pumps (CSII): continuous subcutaneous infusion via cannula; programmable basal rates; delivers boluses on demand

• Inhaled insulin: Afrezza — ultra-rapid inhaled insulin for bolus use; not suitable for all patients

• Hybrid Closed-Loop (HCL) Systems — Detail

• HCL systems integrate a CGM, insulin pump, and control algorithm to automatically modulate basal insulin delivery. The user still announces meals and administers bolus insulin, but the system handles background adjustments autonomously.

•  

• CamAPS FX (CamDiab)

• Developed by the University of Cambridge; CE-marked; widely used in UK

• Adaptive model predictive control (MPC) algorithm; learns individual patterns over days

• Compatible with: Dana-i or Dana-RS pump + Dexcom G6 or G7

• NHS England: funded for all under 18s with T1D from April 2023; expanding to adults

• Includes dedicated pregnancy mode; specific elderly and toddler algorithms

• Ease feature allows temporary increase in target glucose (e.g. during exercise)

•  

• Medtronic MiniMed 780G

• Auto-correction boluses every 5 minutes in addition to basal adjustment — more aggressive automation

• Default target 5.5 mmol/L (100 mg/dL); adjustable

• Compatible with Guardian 4 CGM (factory-calibrated, no finger-prick needed)

• SmartGuard algorithm; meal detection assists even without bolus announcement

•  

• Tandem t:slim X2 with Control-IQ

• Automatic basal rate adjustments + correction boluses when glucose predicted to exceed 10 mmol/L

• Automatic 80% basal reduction when glucose predicted to fall below 3.9 mmol/L

• Sleep mode increases automation and targets tighter overnight range

• Updatable via software (touchscreen pump; over-the-air updates)

•  

• Omni pod 5 (Insulet)

• Tubeless patch pump — no tubing; pod adheres directly to skin for up to 3 days

• SmartAdjust algorithm; controlled via dedicated handset or compatible Android phone

• Compatible with Dexcom G6; activity mode reduces insulin for exercise

•  

• Open-Source / DIY Closed-Loop Systems

• Pioneered by the #WeAreNotWaiting community from 2014 onwards

• Loop (iOS): uses RileyLink/OrangeLink with compatible Omnipod Eros or older Medtronic pumps + Dexcom CGM

• AndroidAPS (AAPS): highly configurable; runs on Android phone; supports multiple pumps; oref1 algorithm with SMBs

• iAPS / Trio: advanced fork of OpenAPS/Loop; dynamic ISF and CR adjustment using Logarithmic algorithm

• Not CE-marked or NHS-approved for general use; used under informed consent by experienced users

• Vibrant online community via Facebook groups, Discord, and openaps.org

• Patch pumps: tubeless devices (Omnipod) worn directly on skin; controlled via smartphone

• Teplizumab (Tzield) — Disease Modification

• Anti-CD3 monoclonal antibody; modulates autoreactive T-cells to slow beta cell destruction

• FDA approved November 2022 — first drug to delay onset of Stage 3 T1D

• Delays clinical diagnosis by a median of >2 years in Stage 2 T1D (TNFAIP3 trial)

• 14-day IV infusion; side effects include transient lymphopenia, rash, mild cytokine release

• Under regulatory review in EU and UK; not yet NHS approved

•  

• Immunotherapy in New-Onset T1D

• Abatacept (CTLA-4 Ig): slows C-peptide decline; ongoing trials in new-onset T1D

• Anti-thymocyte globulin (ATG): single-dose immunotherapy preserving beta cell function at diagnosis

• GAD-alum (Diamyd): antigen-specific immunotherapy; Phase 3 trials; combined with vitamin D

• Combination immunotherapy approaches (e.g. teplizumab + GAD-alum) show additive promise

•  

• Beta Cell Replacement

• Islet transplantation: established therapy for severe hypoglycaemia unawareness; requires lifelong immunosuppression; limited by donor supply

• Vertex VX-880 / VX-264: stem cell-derived fully differentiated beta cells; remarkable Phase 1/2 results (2023–24) — some participants achieving insulin independence

• VX-264 encapsulation device: aims to protect transplanted cells from immune attack — eliminating need for immunosuppression

• Sernova Cell Pouch: implantable scaffold facilitating islet transplantation with reduced immunosuppression

•  

• Gene Therapy and Precision Medicine

• CRISPR/Cas9 gene editing: engineering immune tolerance or producing insulin in non-beta cells (liver, intestinal K-cells)

• HLA-specific cell therapies: producing patient-specific beta cells resistant to autoimmune attack

• Precision medicine: pharmacogenomics to tailor immunotherapy based on HLA type and autoantibody profile

•  

• Glucose-Responsive ('Smart') Insulin

• Insulin analogues that automatically activate when blood glucose rises and inactivate when it normalises

• NNC2215 (Novo Nordisk): glucose-responsive insulin demonstrating proof-of-concept in Phase 2 trials

• Potential to eliminate hypoglycaemia from insulin therapy entirely

• Weekly or monthly ultra-long acting depot formulations in development (insulin icodec — weekly basal)

•  

• T1D Screening Programmes

• ELSA (Early Surveillance for Autoimmune Diabetes) — NHS England programme offering autoantibody screening to relatives of people with T1D

• Germany's Fr1da study: population-wide screening in children; identifies Stage 1–2 T1D enabling education and future preventive therapy

• Goal: prevent DKA at diagnosis; allow access to disease-modifying therapy; inform family planning